Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 15/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14719869 | 0.83 | KDM4E (0.37) | KDM4EALDH1A1HPGDHSD17B10KCNJ1 | |
| SCHEMBL286934 | 0.80 | KCNJ1 (0.44) | KCNJ1 | |
| SCHEMBL14726382 | 0.77 | KCNJ1 (0.40) | KCNJ1 | |
| SCHEMBL14726385 | 0.77 | KCNJ1 (0.40) | KCNJ1 | |
| SCHEMBL14726377 | 0.77 | KCNJ1 (0.40) | KCNJ1 | |
| SCHEMBL14726375 | 0.77 | KCNJ1 (0.40) | KCNJ1 | |
| SCHEMBL14719955 | 0.76 | KCNJ1 (0.44) | KDM4EALDH1A1HPGDHSD17B10KCNJ1 | |
| SCHEMBL15879111 | 0.75 | KCNJ1 (0.51) | KCNJ1 | |
| SCHEMBL15879421 | 0.75 | KCNJ1 (0.51) | KCNJ1 | |
| SCHEMBL4592838 | 0.73 | ALDH1A1 (0.42) | P2RX7KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383399-A1 | USES OF PYRIMIDO-PYRIMIDAZINONES TO TREAT CANCER | Asana BioSciences, LLC (US) | 2018-10-10 | — | — | EP | claimed |
| WO-2017095898-A1 | USES OF PYRIMIDO-PYRIMIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | WO | claimed |
| EP-2748166-A1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | Endo Pharmaceuticals Inc. (US) | 2014-07-02 | — | — | EP | claimed |
| WO-2013028818-A1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | ENDO PHARMACEUTICALS INC. (US) | 2013-02-28 | — | — | WO | claimed |
| EP-2744499-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2790511-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9206199-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9062070-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140336177-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-11-13 | — | — | US | disclosed |
| EP-2790511-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140206618-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-07-24 | — | — | US | disclosed |
| EP-2744499-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013090271-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013028474-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206618-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | P2RX7 616/4885KDM4E 2454/4885ALDH1A1 1462/4885 |
| US-20140336177-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | P2RX7 546/4885KDM4E 2161/4885ALDH1A1 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.